IBIO iBio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%
Returns
ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $100,000 | $400,000 |
| R&D expense | $19.64M | $8.31M |
| SG&A expense | $10.60M | $10.69M |
| Operating income | -$35.14M | -$18.60M |
| Interest expense | $53,000 | $212,000 |
| Pretax income | -$33.04M | -$18.38M |
| Income tax | $0 | $0 |
| Net income | -$33.04M | -$18.38M |
| EBITDA | -$34.58M | -$18.12M |
| EPS (basic) | -0.32 | -1.75 |
| EPS (diluted) | -0.32 | -1.75 |
| Weighted avg. shares (diluted) | 104.06M | 10.50M |
| Balance sheet | ||
| Cash & equivalents | $56.40M | $8.79M |
| Short-term investments | $31.64M | $0 |
| Receivables | — | $0 |
| Current assets | $92.22M | $9.72M |
| PP&E, net | $3.09M | $3.16M |
| Intangibles | $1.82M | $6.85M |
| Total assets | $99.11M | $23.18M |
| Current liabilities | $11.74M | $6.11M |
| Total liabilities | $13.40M | $8.30M |
| Shareholders' equity | $85.71M | $14.88M |
| Shares outstanding | 55.70M | 19.35M |
| Cash flow statement | ||
| Operating cash flow | -$23.22M | -$15.30M |
| Capital expenditure | $578,000 | $16,000 |
| Free cash flow | -$23.80M | -$15.32M |
| Investing cash flow | -$32.00M | $742,000 |
| Financing cash flow | $103.05M | $8.93M |
| Depreciation & amortization | $558,000 | $484,000 |
| Stock-based compensation | $1.37M | $1.53M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.